The evidence that does exist belongs to the parent compounds and must be tiered honestly: Semax: registered in Russia (a national approval, not FDA/EMA) for ischemic stroke and related indications, supported mainly by Russian clinical studies that are frequently non-randomized, open-label, or small, plus a substantial preclinical literature
1 Whether a gastrointestinal signal built for brief, prandial spikes behaves the same way when it is switched on permanently is not a rhetorical question
The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Pharmaceuticals
Key unknowns include: Whether the heart rate increase persists, resolves or has any long-term cardiovascular implications The full effect on liver and metabolic health over extended treatment Whether bone density is affected (significant weight loss can reduce bone mineral density regardless of the method) Any potential effects on the pancreas pancreatitis has been a monitored concern across all GLP-1 medications What happens when someone stops taking retatrutide (weight regain patterns, metabolic rebound) Phase 3 trials, including the large TRIUMPH programme, are designed to answer many of these questions
Supports Collagen Production: It reduces the damage done by free radicals that deplete collagen